​Efficacy Of Teneligliptin As Add-On Therapy In Patients With Type 2 Diabetes Mellitus And Chronic Kidney Disease: A Real-World Experience

ABSTRACT

Introduction: Type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD) is dreadful combination necessitatingadequate glycemic control to prevent further complications. Teneligliptin is found to be renal friendly antidiabetic agent whichcan provide effective glycemic control.Objective: The objective of this study was to determine the efficacy of teneligliptin as add-on to existing therapy in patients ofT2DM with CKD.Materials and Methods: This was a retrospective study where patients with T2DM and CKD who received teneligliptin wereincluded in the study. Changes in glycemic parameters such as hemoglobin A1c (HbA1c) (%), fasting plasma glucose (FPG),and postprandial plasma glucose (PPG) and change in estimated glomerular filtration rate (eGFR) were analyzed.Results: In total, 66 patients were included in analysis. Mean age was 57.7 ± 14.0 years and 60.6% were males. BaselineHbA1c, FPG, and PPG levels were 7.8 ± 0.7%, 128.0 ± 25.5 mg/dl, and 214.0 ± 55.9 mg/dl, respectively. There was a significantreduction in HbA1c at 3 and 6 months (mean difference from baseline −0.9 ± 0.5 and −1.2 ± 0.5 respectively, P < 0.001 forboth). Similarly, mean change in FPG (−28.4 ± 20.9 and −29.9 ± 24.3 mg/dl, respectively) and PPG (−70.5 ± 49.2 and −97.0 ±60.7 mg/dl, respectively) was also significant (P < 0.001 for all comparisons). The change in eGFR was significant at 3 months(P = 0.049) and 6 months (P = 0.014).Conclusion: Teneligliptin is effective in reducing glycemic burden in patients with T2DM and CKD and can be considered asbe considered among first choices for glycemic control in patients with renal impairment.